174 related articles for article (PubMed ID: 12445249)
21. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
[TBL] [Abstract][Full Text] [Related]
22. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
[TBL] [Abstract][Full Text] [Related]
23. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
24. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
25. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer.
Baekelandt M; Holm R; Nesland JM; Tropé CG; Kristensen GB
J Clin Oncol; 2000 Nov; 18(22):3775-81. PubMed ID: 11078490
[TBL] [Abstract][Full Text] [Related]
26. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
Skírnisdóttir I; Seidal T
Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
29. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
30. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer.
Kodama J; Miyagi Y; Seki N; Tokumo K; Yoshinouchi M; Kobashi Y; Okuda H; Kudo T
Eur J Obstet Gynecol Reprod Biol; 1999 Jan; 82(1):107-10. PubMed ID: 10192497
[TBL] [Abstract][Full Text] [Related]
31. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma.
Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB
Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853
[TBL] [Abstract][Full Text] [Related]
32. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic significance of expression of p53, bcl-2 and bax in squamous epithelial carcinoma of the larynx--a multivariate analysis].
Jäckel MC; Sellmann L; Youssef S; Dorudian MA; Füzesi L
HNO; 2001 Mar; 49(3):204-11. PubMed ID: 11320623
[TBL] [Abstract][Full Text] [Related]
34. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.
Marx D; Binder C; Meden H; Lenthe T; Ziemek T; Hiddemann T; Kuhn W; Schauer A
Anticancer Res; 1997; 17(3C):2233-40. PubMed ID: 9216694
[TBL] [Abstract][Full Text] [Related]
38. High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.
Tan L; Sha L; Hou N; Zhang M; Ma Q; Shi C
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31152111
[TBL] [Abstract][Full Text] [Related]
39. The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer.
Avraam K; Pavlakis K; Papadimitriou C; Vrekoussis T; Panoskaltsis T; Messini I; Patsouris E
Eur J Gynaecol Oncol; 2011; 32(5):516-20. PubMed ID: 22053665
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
